Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - tocilizumab - infusion, solution concentrate - 20mg/ml - tocilizumab 20mg/ml

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppressants - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone.covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml.periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret should be given in combination with colchicine, if appropriate.still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids.kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - tocilizumab -

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - tocilizumab - injection, solution - tocilizumab 162 mg/0.9 ml

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - sotrovimab (unii: 1mtk0bpn8v) (sotrovimab - unii:1mtk0bpn8v) - the secretary of health and human services (hhs) has issued an emergency use authorization (eua) for the emergency use of sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct sars-cov-2 viral testing, and who are at high risk for progression to severe covid-19, including hospitalization or death. however, sotrovimab is not approved for this use (i.e., sotrovimab has not been demonstrated to be safe and effective for this use). limitations of authorized use benefit of treatment with sotrovimab has not been observed in patients hospitalized due to covid‑19. sars-cov-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with covid‑19 requiring high flow oxygen or mechanical ventilation [see warnings and precautions (5.2)] . sotrovimab is not fda-approved for any use, including for the treatment of covid-19.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

gilead sciences south africa (pty) ltd - infusion (parenteral) - see ingredients - each vial contains remdesivir 100,0 mg

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - molnupiravir (unii: ya84ki1vew) (molnupiravir - unii:ya84ki1vew) - the u.s. food and drug administration (fda) has issued an emergency use authorization (eua) to permit the emergency use of the unapproved product lagevrio™ for treatment of adults with mild-to-moderate coronavirus disease 2019 (covid-19): - who are at high risk for progression to severe covid-19, including hospitalization or death. refer to cdc website1 for additional details, and for - whom alternative covid-19 treatment options approved or authorized by fda are not accessible or clinically appropriate. limitations of authorized use - lagevrio is not authorized for use in patients who are less than 18 years of age [see warnings and precautions (5.3)] . - lagevrio is not authorized for initiation of treatment in patients hospitalized due to covid-192. benefit of treatment with lagevrio has not been observed in subjects when treatment was initiated after hospitalization due to covid-19 [see dosing and administration (2.1)] . - lagevrio is not authorized for use for longer than 5 consecutive days. - lagevrio is

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - nirmatrelvir (unii: 7r9a5p7h32) (nirmatrelvir - unii:7r9a5p7h32) - the u.s. food and drug administration (fda) has issued an emergency use authorization (eua) for the emergency use of paxlovid for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) with mild-to-moderate coronavirus disease 2019 (covid-19) and who are at high risk1 for progression to severe covid-19, including hospitalization or death. limitations of authorized use paxlovid is not authorized for use as pre-exposure or post-exposure prophylaxis for prevention of covid-19 [see clinical studies (14.3)] . paxlovid may be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs. paxlovid may also be prescribed for an individual patient by a state-licensed pharmacist under the following conditions: the state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced